This multifactorial improvement of liver disease noted when combining both drugs suggests that a course of treatment that includes both reduced FSP27 activity and activation of PPARα could provide therapeutic benefit to patients with NAFLD/NASH. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.